Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cidara Therapeutics, Inc. (CDTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.4490-0.0396 (-8.10%)
At close: 04:00PM EDT
0.4972 +0.05 (+10.73%)
After hours: 04:51PM EDT
Advertisement

Cidara Therapeutics, Inc.

6310 Nancy Ridge Drive
Suite 101
San Diego, CA 92121
United States
858 752 6170
https://www.cidara.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees89

Key Executives

NameTitlePayExercisedYear Born
Dr. Jeffrey L. Stein Ph.D.Pres, CEO & Exec. Director836.4kN/A1955
Dr. Taylor SandisonChief Medical Officer597.9kN/A1972
Dr. Les Tari Ph.D.Chief Scientific Officer845.1kN/AN/A
Dr. Kevin M. Forrest Ph.D.Founder and Chief Strategy OfficerN/AN/A1977
Dr. Preetam Shah M.B.A., Ph.D.CFO, Chief Bus. Officer & Principal Accounting OfficerN/AN/A1973
Mr. Paul DaruwalaChief Operating OfficerN/AN/A1969
Mr. Shane M. WardChief Legal Officer & Corp. Sec.N/AN/A1975
Ms. Allison Lewis CCP, SPHRVP of HRN/AN/AN/A
Dr. Kenneth F. Bartizal Ph.D.Chief Devel. OfficerN/AN/A1951
Mr. James M. BalkovecSr. VP of ResearchN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Corporate Governance

Cidara Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement